CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Caris Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$30.71+0.15 (+0.49%)
Close on Oct 19, 2026
- Market cap
- $8.69B
- P/E (TTM)
- –
- Dividend yield
- –
Caris Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Cost of services - Molecular profiling services | $952.77M | $863.44M | $766.72M | $579.02M | $465.23M | $389.96M | $349.12M | 96.3% | +104.8% |
| Cost of services - Pharma research and development services | $36.84M | $43.85M | $45.31M | $70.05M | $68.62M | $62.54M | $63.15M | 3.7% | -46.3% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $980.19M | $896.80M | $801.39M | $636.78M | $522.64M | $441.84M | $401.84M | 99.0% | +87.5% |
| International | $9.42M | $10.50M | $10.64M | $12.28M | $11.21M | $10.66M | $10.42M | 1.0% | -16.0% |
From the segment and revenue-disaggregation notes of Caris Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.